Biogen Inc (BIIB) Institutional Holdings & 13F Data (Q2 2026)

BIIB ranks #441 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1056 institutions disclose a position in BIIB, but none treat it as a major bet — even Primecap Management Co/ca/, its most concentrated holder, allocates just 1.9% of its own portfolio to it.

Fidelity has added to its BIIB position for two straight quarters, increasing it by $2.3B to reach $3.9B today.

Steve Cohen has trimmed its BIIB position for two straight quarters, cutting it by $652.2M while still holding $19.2M.

BIIB is up 3.1% today, and institutions have been net buyers of $9.6B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

BIIB posted net income of $1.4B over the trailing twelve months, and currently trades at a P/E of 23.9.

• Profitable — net income of $1.4B over the trailing twelve months
• Revenue grew 1.2% year over year
• Net income declined year over year, from $1.5B to $1.4B
• Generated $2.2B in positive operating cash flow
• Current ratio of 2.68x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.61x equity — within a conventional range